US Recall News

United States Recall News Alerts for Recalled Drugs, Food, Products, & Vehicles

MENUMENU
  • Home
  • About
    • Advertise
  • Full Recall News Archive
    • Top Story

      J&J Settles Talc Mesothelioma Settlement

      By Sandra Dalton, Staff Writer On January 6, 2020, Superior Court Judge Stephen Kaus announced that Johnson & Johnsons (J&J) had agreed to … [Read More...]

      Daiso Issues Alergy Alert for Prepackaged Snacks

      Summary Company Announcement Date: February 03, 2023 FDA Publish Date: … [Read More...]

    • More Safety Articles
    • Federal Preemption of State Product Liability Law
  • Drug Recalls
    • Abilify
    • Benicar
    • Fluoroquinolones
    • Invokana
    • Lipitor
    • Nuplazid
    • Opioids
    • OxyContin
    • Pradaxa
    • Proton Pump Inhibitors (PPIs)
    • Risperdal
    • SSRI
    • Symptoms & Side Effects
    • Taxotere
    • Testosterone
    • Uloric
    • Valsartan
    • Xarelto
    • Zofran
  • Medical Devices
    • 3M Earplug
    • 3T Heater-Cooler System
    • Bair Hugger
    • Bipolar Hip System
    • Essure
    • Hip Replacements
    • Implanon
    • IVC Filters
    • Hernia Mesh
    • Power Morcellators
    • Shoulder Implants
    • Transvaginal Mesh
  • Food Recalls
    • FDA Press Releases
    • USDA Press Releases
  • Auto Recalls
    • Air Bags
    • Ignitions
    • NHTSA Press Releases
    • Off-Road Utility Vehicles
    • Snowmobiles
    • Tires
  • Other Products
    • Asbestos
    • Baby Products
    • Pet Products
    • Roundup
    • Talcum Powder
    • Toy Recalls
You are here: Home / Drug Recalls / Nuplazid / FDA Will ‘Take Another Look’ at Controversial Parkinson’s Drug

FDA Will ‘Take Another Look’ at Controversial Parkinson’s Drug

May 7, 2018 By Sean Lally Leave a Comment

Parkinsons

When, two years ago, the FDA reviewed the Parkinson’s drug, Nuplazid, lead medical reviewer Dr. Paul Andreason issued grave warnings about the potential risks. During the review process, he observed that those taking the actual medication were suffering extreme side-effects (including death) twice as much as those taking placebos. In addition, he noted, he wasn’t sure the potential public health benefits outweighed the risks, as is necessary when approving a drug as a “breakthrough therapy” – a relatively new designation meant to speed up the FDA approval process for medications that could substantially improve the lives of seriously (or terminally) ill patients.

Tyne’s Plea

A lengthy CNN report published in April outlined the trials and tribulations of the process, highlighting the story of one Brendan Tyne whose mother suffers from Parkinson’s disease psychosis and as a result “thinks there are people in the house and animals [that] are trying to get her.”

Nuplazid – designed to treat such mental conditions – emerged as a potential savior for Tyne. He told the FDA panel about his two young children and his desire for them to know their grandmother: “If nothing is done to bring her back to some semblance of normalcy, my children will never remember their grandmother for who she is.” He continued, “Please, I beg you, do not deprive my children and their grandmother of experiencing that love.”

Hesitant Approval

The drug was approved in a 12-2 vote, with a number of committee members expressing ambivalence on the matter. Several members figured any drug was better than no drug, as no other medication exists for the treatment of Parkinson’s disease psychosis. At least one member suggested a broader study “so we can ensure that, once it goes into real-world use, that the benefits will outweigh the risks.”

Adverse Events

The results have not been encouraging. Tyne’s mother’s condition did not improve; rather, it severely worsened. As people purchased the drug – to the tune of $125 million – nearly 1,000 adverse event reports poured into the agency. It seemed the drug was having the opposite effect for a lot of people. One non-profit organization found that 244 deaths had been linked to Nuplazid, leading one scientist associated with the non-profit to call for a more substantial review of the drug.

Gottlieb’s Hearing

It would appear that a review has been commenced. According to a recent CNN report, FDA Administrator Scott Gottlieb assured Congressional leaders at a budget hearing that the agency was “tak[ing] another look” at the medication and that a review had begun several weeks prior. Though the drug has been linked to a number of adverse events, it cannot be said for certain that Nuplazid was the main culprit in those cases. However, the data surrounding those events can be used by the FDA to take decisive action. For instance, the agency might enforce the use of a more pronounced warning label – known as a Black Box Warning.

Suspect

For now, the Parkinson’s medication has not been definitively named the cause of the deaths, but it has been labeled a “suspect” drug. According to the FDA, many of the adverse event reports have involved elderly patients who have been suffering from the disease for a long time. In addition, many of the patients were diagnosed with other conditions and were taking other drugs in combination with Nuplazid.

Congressional Pressure

Despite the FDA’s caveats about the age and condition of the patients, Representative Rose Delauro (a Democrat from Connecticut) pressed Gottlieb on the agency’s actions – or lack thereof. “How many more adverse events do we have to have reported, and how many people quite frankly have to die? Why does the industry always take precedence over public health and safety?” she asked the cabinet member.

One might wonder whether the “breakthrough therapy” designation – which has helped expedite the approval process for over 200 drugs – will be subject to further criticism.

Share this:

  • Facebook
  • Twitter
  • LinkedIn
  • Email
  • Print

Related

Filed Under: Drug Recalls, Nuplazid

About Sean Lally

Sean Lally holds a BA in Philosophy from Temple University where he also studied theatre for several years. Between 2007 and 2017, he worked as a professional actor for several regional theater companies in Philadelphia, including the Arden Theatre Co., EgoPo Productions, Lantern Theater and the Bearded Ladies. In 2010, Sean co-founded Found Theater Company, an avant-garde artist collective with whom he first started to cultivate an identity as a writer.

Leave a Reply Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Facebook
Thomas Roney LLC
Economic Consulting

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Daiso Issues Alergy Alert for Prepackaged Snacks

February 3, 2023 By The FDA

Fresh Ideation Food Group LLC Recalls Sandwiches and Other Products Because of Possible Health Risk

February 3, 2023 By The FDA

Global Pharma Healthcare Issues Voluntary Nationwide Recall of Artificial Tears Lubricant Eye Drops Due to Possible Contamination

February 2, 2023 By The FDA

Hero Highlight

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Children’s Robes Recalled Due to Violation of Federal Flammability Standards and Burn Hazard; Imported by BTPEIHTD; Sold Exclusively at Amazon.com

February 1, 2023 By The CPSC

Children’s Robes Recalled Due to Violation of Federal Flammability Standards and Burn Hazard; Imported by ChildLikeMe; Sold Exclusively at Amazon.com

February 1, 2023 By The CPSC

Children’s Robes Recalled Due to Violation of Federal Flammability Standards and Burn Hazard; Imported by SGMWVB Brand; Sold Exclusively on Amazon.com

February 1, 2023 By The CPSC

Shop Me Ca Recalls “Diep Bao Cream” Because of Possible Health Risk

February 1, 2023 By The FDA

B&G Foods Issues Voluntary Allergy Alert for Undeclared Peanut in Three Cases of Back to Nature® Fudge Mint Cookies

January 31, 2023 By The FDA

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Shop Me Ca Recalls “Diep Bao Cream” Because of Possible Health Risk

February 1, 2023 By The FDA

B&G Foods Issues Voluntary Allergy Alert for Undeclared Peanut in Three Cases of Back to Nature® Fudge Mint Cookies

January 31, 2023 By The FDA

IBSA Pharma Inc. Issues Voluntary Nationwide Recall of Select Lots of TIROSINT®-SOL (levothyroxine sodium) Oral Solution Due to Subpotency

January 30, 2023 By The FDA

Recall News in Your Inbox

Enter your email address to receive automated recall news updates.

Recent Comments

  • Roger McGowan on ABH NATURE’S PRODUCTS, INC, ABH PHARMA, INC., and STOCKNUTRA.COM, INC. Issues Nationwide Recall of All Lots of Dietary Supplement Products
  • Kathryn Moore on FDA Wants Cancer Warning on Breast Implants
  • BRAD on Huge ATV Recall by Polaris – Sportsman and Scrambler
  • Crystal Anderson on Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants and Tissue Expanders
  • Outsourcing Training on The Modern Marketing of Pain
  • SANDRA Collett on Processed Food Preservative Linked to Autism?
  • Eric Karsh on Health Risks of Roundup Go Well Beyond Cancer

Recent Posts

  • Daiso Issues Alergy Alert for Prepackaged Snacks
  • Fresh Ideation Food Group LLC Recalls Sandwiches and Other Products Because of Possible Health Risk
  • Global Pharma Healthcare Issues Voluntary Nationwide Recall of Artificial Tears Lubricant Eye Drops Due to Possible Contamination
  • Paper Cape Recalls Children’s Pajamas Due to Violation of Federal Flammability Standards and Burn Hazard
  • Children’s Robes Recalled Due to Violation of Federal Flammability Standard and Burn Hazard; Imported by Betusline Official Apparel; Sold Exclusively on Amazon.com
  • Children’s Robes Recalled Due to Violation of Federal Flammability Standards and Burn Hazard; Imported by BTPEIHTD; Sold Exclusively at Amazon.com
  • Children’s Robes Recalled Due to Violation of Federal Flammability Standards and Burn Hazard; Imported by ChildLikeMe; Sold Exclusively at Amazon.com
  • Children’s Robes Recalled Due to Violation of Federal Flammability Standards and Burn Hazard; Imported by SGMWVB Brand; Sold Exclusively on Amazon.com
  • Shop Me Ca Recalls “Diep Bao Cream” Because of Possible Health Risk
-- See More Recall News

Disclaimer: The information contained in these topics is not intended nor implied to be a substitute for professional medical or legal advice, it is provided for educational purposes only. Always seek the advice of your physician or other qualified healthcare provider about any questions you may have regarding a medical condition. Nothing contained in these topics is intended to be used for medical diagnosis or treatment.


ATTORNEY ADVERTISING. The information provided on this website is not legal advice. No attorney-client relationship is formed by the use of this site. It is not stated or implied that a lawyer is certified as a specialist in any particular field of law. No results are guaranteed, and prior results do not guarantee a similar outcome. This site is informational, only, not dispositive; it is up to you to decide whether a particular lawyer is right for you. Use of this site is subject to your agreement to these.


Copyright © 2023 Altrumedia · Terms of Service · Log in